
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana has demonstrated a positive trajectory in its earnings potential, with an increased 2025 EPS estimate raised to $17.06, reflecting strong second-quarter results and revised guidance. Furthermore, the company anticipates year-over-year earnings growth in 2027 driven by effective margin initiatives, solidifying its operational efficiency despite potential challenges in bonus payments. Humana's above-industry star rating profile in the Medicare Advantage segment positions the firm competitively, enabling resilience against regulatory and reimbursement fluctuations.
Bears say
Humana's financial outlook appears negative due to anticipated declines in earnings per share (EPS) for 2026, attributed to ongoing challenges such as increased Medicare Advantage (MA) utilization and heightened competition, which complicate margin recovery initiatives. The company is also facing potential headwinds from inadequate reimbursement rates and declining Star ratings, which could further impact its financial performance and growth in Healthcare Services. Adjustments to EPS estimates reflect concerns over sustaining profitability amid these operational challenges, with projections for FY27 indicating a possible shortfall of approximately 10% due to necessary investments for recovery efforts.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares